Meta-analysis from these studies showed that treatment utilizing SYK and/or BTK inhibitors was associated with higher risk of obtaining overall platelet response compared to placebo for adult ITP patients (RR 3.95; 95%CI: 2.68 – 5.81, p<0.00001, I2 = 0%, random-effect model) (Figure 2B) (Table 3). This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.